



NDA 202450/S-011

**SUPPLEMENT APPROVAL**

AstraZeneca Pharmaceuticals LP  
One MedImmune Way  
Gaithersburg, MD 20878

Attention: Steve Danielson, MBA  
Senior Director, Global Regulatory Affairs

Dear Mr. Danielson:

Please refer to your Supplemental New Drug Application (sNDA) dated May 9, 2018, received May 9, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tudorza Pressair (aclidinium bromide inhalation powder).

This Prior Approval supplemental new drug application provides for revisions to the Instructions for Use (IFU) of the label.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, Instructions for Use), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sadaf Nabavian, Regulatory Project Manager, at 301-796-2777.

Sincerely,  
*{See appended electronic signature page}*  
Sally Seymour M.D.  
Acting Director  
Division of Pulmonary, Allergy, and  
Rheumatology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

### ENCLOSURE(S):

- Content of Labeling
- Prescribing Information
- Patient Package Insert
- Instructions for Use

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

BANU A KARIMI SHAH

11/09/2018

signing with the delegated authority of Dr. Sally Seymour, Acting Division Director, DPARP